Tassone, Pierfrancesco
Di Martino, Maria Teresa
Arbitrio, Mariamena
Fiorillo, Lucia
Staropoli, Nicoletta
Ciliberto, Domenico
Cordua, Alessia
Scionti, Francesca
Bertucci, Bernardo
Salvino, Angela
Lopreiato, Mariangela
Thunarf, Fredrik
Cuomo, Onofrio
Zito, Maria Cristina
De Fina, Maria Rosanna
Brescia, Amelia
Gualtieri, Simona
Riillo, Caterina
Manti, Francesco
Caracciolo, Daniele
Barbieri, Vito
Di Paola, Eugenio Donato
Di Francesco, Adele Emanuela
Tagliaferri, Pierosandro
Funding for this research was provided by:
Associazione Italiana per la Ricerca sul Cancro (n. 9980)
Article History
Received: 25 December 2022
Accepted: 16 June 2023
First Online: 26 June 2023
Declarations
:
: The clinical study protocol has been approved by the Regulatory Authorities AIFA/ISS (Italy) (AIFA/SC/P/34930-27/05/2018, amendment AIFA/SC/P/4261—15/01/2020) and by the local Ethics Committee (n. 207-19/07/2018, amendment n.18 -16/01/2020). All patients wrote an informed consent to participate in the study.
: P.T., M.T.D.M., and P.T. are inventors of patents (US 9,404,111 B2; EPO 2943570; C.C.I.A.A. 0001429326) that are owned by Magna Graecia University, Catanzaro, Italy. All other authors declare no competing interests.